8-K: Blade Sells Passenger Unit to Joby, Rebrands as Strata Medical

Blade Air Mobility announced the sale of its passenger division to Joby Aviation for up to $125 million, pivoting to a pure-play medical services and logistics business under the new brand Strata Critical Medical.

Summary

• Blade Air Mobility, Inc. (Blade) entered into an Equity Purchase Agreement to sell its Passenger business to Joby Aero, Inc., a wholly-owned subsidiary of Joby Aviation, Inc.
• The Passenger business includes Blade's operations in the US and Europe, lounges, terminals, and the Blade brand, focusing on arranging passenger transportation on third-party operated aircraft.
• The consideration for the sale is up to $125 million, payable in cash or Joby Aviation common stock, at Joby's option.
• An initial payment of $90 million will be received upon closing, subject to adjustments and customary indemnity holdbacks.
• Up to an additional $35 million is available as an earn-out, contingent on the satisfaction of certain employee retention and financial performance targets over 18 and 12 months, respectively, following the closing.
• Following the divestiture, Blade's Medical division will remain public and rebrand as Strata Critical Medical (Strata), focusing entirely on its contractual medical services and logistics business.
• Trinity Medical Solutions, Blade's operating business in the Medical segment and a major air transporter of human organs for transplant in the U.S., will remain Strata's wholly-owned subsidiary.
• The divestiture is expected to be Adjusted EBITDA and Free Cash Flow neutral for Strata, supported by approximately $7 million in estimated annual corporate cost efficiencies.
• A long-term partnership between Joby and Strata will provide Strata with future access to Joby's eVTOL aircraft for medical use.
• Robert Wiesenthal, Blade's Founder and CEO, will join Joby as CEO of the acquired Blade Air Mobility passenger business and will also serve as Chairman of the Board of Strata.
• Melissa Tomkiel, Blade's President and General Counsel, and William Heyburn, Blade's Chief Financial Officer and Head of Corporate Development, will assume roles as Co-Chief Executive Officers of Strata, while retaining their current respective roles.

Sentiment

Score: 8

Explanation: The filing indicates a highly strategic and positive shift for Blade, divesting a less profitable segment to focus on a high-growth, high-margin medical logistics business. The transaction provides significant capital and a strategic partnership for future eVTOL integration, positioning the company for more focused and resilient growth.

Positives

• The divestiture allows Blade to become a pure-play, asset-light medical services and logistics business, focusing on its fastest-growing and most profitable segment.
• The medical segment represented approximately 84% of 2024 Segment Adjusted EBITDA and 59% of 2024 Revenue, indicating a strategic shift towards a higher-margin business.
• The transaction is expected to be Adjusted EBITDA and Free Cash Flow neutral for Strata, with an estimated $7 million in annual corporate cost efficiencies.
• The long-term partnership with Joby Aviation provides Strata with potential future access to eVTOL aircraft for medical use, offering quiet capabilities and lower operating costs compared to traditional rotorcraft.
• The medical business operates in markets not correlated with the overall macro environment, providing stability and resilience.
• Strata boasts a 100% contracted customer retention rate over the last twelve months in its medical segment.

Negatives

• The earn-out portion of up to $35 million is contingent on performance and retention metrics, meaning the full $125 million consideration is not guaranteed.
• The company will lose revenue and market presence from its passenger air mobility business.

Risks

• The occurrence of any event, change, or circumstance that could give rise to the termination of the Purchase Agreement or the Transition Agreement, or any delay in, or failure to, consummate the Transactions.
• The effect of the announcement of the proposed transaction on business relationships, operating results, and business generally.
• Unexpected costs, charges, or expenses resulting from the proposed divestiture.
• Any failure to realize the anticipated efficiencies and benefits of such transaction.
• Fluctuations in the value of any shares of Joby stock that are issued as part of the consideration.
• Continued incurrence of significant losses by the remaining Strata business.
• Failure of the markets for Strata's offerings to grow as expected, or at all.
• The inability or unavailability to use or take advantage of the shift, or lack thereof, to Electric Vertical Aircraft (EVA) technology.
• Any adverse publicity stemming from accidents involving small aircraft, helicopters, or charter flights, particularly those involving third-party operators.
• Increases in insurance costs or reductions in insurance coverage for Strata or its third-party aircraft operators.
• Reliance on contractual relationships with certain transplant centers and Organ Procurement Organizations for the medical business.
• Regulatory obstacles in local governments or changes in the regulatory environment.
• The expansion of domestic and foreign privacy and security laws, and environmental regulations.
• The loss of key members of the management team or the inability to maintain company culture.
• The ability to identify, complete, and successfully integrate future acquisitions for Strata's expansion.

Future Outlook

Strata Critical Medical will focus on broadening its offerings across the medical logistics and solutions value chain, with significant deployable capital for acquisitions and organic expansion. The company aims to leverage its asset-light platform to provide mission-critical logistics and medical services to hospitals and healthcare providers, with a long-term partnership providing future access to Joby eVTOLs for medical flights.

Management Comments

• Robert Wiesenthal stated that Blade's mission has been to accelerate the transition from traditional rotorcraft to electric aircraft, and there is no stronger company than Joby to make this a reality for all stakeholders. He added that the transaction enables the company to become laser-focused on broadening its offerings across the medical logistics and solutions value chain with a singular strategy and significant deployable capital for acquisitions and organic expansion.
• Melissa Tomkiel emphasized that Strata's end-to-end, time-critical air logistics platform is trusted by more organ transplant hospitals than any other provider, and the company will remain relentless in supporting its life-saving customers, evidenced by a 100% contracted customer retention rate over the last twelve months.
• William Heyburn noted that the divestiture allows the company to focus entirely on Medical, its fastest-growing and most profitable business line, and that Strata will be a pure-play, contractual medical business operating in rapidly growing markets not correlated with the overall macro environment.

Industry Context

This announcement signifies a strategic pivot within the air mobility sector, with Blade divesting its consumer-facing passenger flight business to focus exclusively on the specialized and high-growth medical logistics segment. This move aligns with a broader trend of companies specializing in niche, high-value services, particularly those leveraging advanced air mobility technologies like eVTOLs. Joby's acquisition of Blade's passenger division strengthens its position in the urban air mobility market, while Strata's focus on medical transport positions it in a critical, less economically sensitive sector with potential for eVTOL integration.

Management Changes

Corporate Governance

Related Party Transactions

• Robert Wiesenthal's compensation package, including a pro-rata annual bonus, a $3,750,000 transaction bonus, and vesting terms for his PSUs and RSUs, is detailed in connection with his transition.
• Robert Wiesenthal will receive $375,000 in flight credits for personal travel on flights with the acquired Passenger business.
• Blade will reimburse Robert Wiesenthal up to $75,000 in legal fees incurred for negotiating the Transition Agreement.
• All 'Affiliate Arrangements' (contracts, arrangements, commitments, or transactions between a Related Person and any Transferred Entity) are to be settled, terminated, and canceled without further liability to the Transferred Entities from and after the Closing, with exceptions for certain surviving obligations.
• All 'Intercompany Accounts' (intercompany receivables, payables, and loans) between Transferred Entities and Seller/Affiliates are to be settled in full and/or terminated as of the Closing.

Stakeholder Impact

• **Shareholders**: Will see a significant strategic shift, with the company focusing on the medical logistics sector. The transaction provides cash and potential Joby stock, and the new Strata entity aims for focused growth and profitability.
• **Employees**: Robert Wiesenthal transitions to a new role at Joby and Strata. Other key executives, Melissa Tomkiel and William Heyburn, are promoted to Co-CEOs of Strata. Employee retention is a key condition for the transaction, with Key Employees and 90% of other Business Employees expected to remain employed by the Transferred Entity.
• **Customers (Passenger Business)**: The passenger business and Blade brand will be acquired by Joby Aviation, with operations continuing as a standalone entity within Joby, suggesting continuity of service under new ownership.
• **Customers (Medical Business)**: Medical customers will benefit from Strata's laser focus on expanding its offerings and strengthening its services in critical medical logistics, with potential future integration of eVTOL technology.
• **Suppliers/Operators**: The transaction involves a shift in contractual relationships, with the acquired passenger business operating under Joby and the medical business (Strata) continuing its operations. Non-compete clauses will affect Blade's future engagement with certain operators in passenger air mobility.

Next Steps

• Consummation of the transaction, expected to close in the coming weeks.
• Rebranding of Blade's Medical division as Strata Critical Medical.
• Announcement of a new ticker symbol for Strata at a later date.
• Robert Wiesenthal to assume new roles as CEO of Joby's acquired Blade Air Mobility and Chairman of Strata's Board.
• Melissa Tomkiel and William Heyburn to assume Co-CEO roles at Strata.
• Strata to pursue acquisitions and organic expansion in the medical logistics and solutions value chain.
• Joby and Strata to negotiate in good faith for Strata's right of first refusal to use Joby eVTOL aircraft for medical transport.

Key Dates

Recommendation

The divestiture of the passenger business allows Blade to pivot entirely to its high-growth, high-margin medical logistics segment, which already contributes significantly to its EBITDA and revenue. This strategic focus, coupled with anticipated cost efficiencies and a forward-looking partnership with Joby for eVTOL integration, positions the newly branded Strata Critical Medical for accelerated and more resilient growth in a less macro-sensitive market. The transaction provides substantial capital and a clear path for future expansion, making it an attractive investment.

Keywords

Blade Air Mobility, Joby Aviation, Strata Critical Medical, Divestiture, M&A, Air Mobility, Medical Logistics, eVTOL, Organ Transport, Aviation, Strategic Shift